BridgeBio Pharma bid to acquire full control of Eidos Therapeutics

13 August 2019

Shares of Eidos Therapeutics (Nasdaq: EIDX) closed up 6.1% at $37.32 yesterday, after it was revealed that, under a non-binding proposal, BridgeBio Pharma (Nasdaq: BBIO) will purchase all of the outstanding common stock of the company not already owned.

BridgeBio currently owns, through its wholly-owned subsidiary, BridgeBio Pharma LLC, around 66.6% of the outstanding shares of the company’s common stock and would acquire the remaining shares for a fixed exchange ratio of 1.30 shares of BridgeBio common stock for each share of Eidos. BridgeBio’s shares closed down 2.6% at $26.19 on Monday.

According to the terms of the proposal, which is subject to certain conditions, BridgeBio would acquire all of the shares of common stock of the company not already owned by BridgeBio for a fixed exchange ratio of 1.30 shares of BridgeBio common stock for each share of Eidos.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK